| Product NDC: | 0003-1968 |
| Proprietary Name: | ZERIT |
| Non Proprietary Name: | stavudine |
| Active Ingredient(s): | 1 mg/mL & nbsp; stavudine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | POWDER, FOR SOLUTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 0003-1968 |
| Labeler Name: | E.R. Squibb & Sons, L.L.C. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA020413 |
| Marketing Category: | NDA |
| Start Marketing Date: | 19960906 |
| Package NDC: | 0003-1968-01 |
| Package Description: | 200 mL in 1 BOTTLE (0003-1968-01) |
| NDC Code | 0003-1968-01 |
| Proprietary Name | ZERIT |
| Package Description | 200 mL in 1 BOTTLE (0003-1968-01) |
| Product NDC | 0003-1968 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | stavudine |
| Dosage Form Name | POWDER, FOR SOLUTION |
| Route Name | ORAL |
| Start Marketing Date | 19960906 |
| Marketing Category Name | NDA |
| Labeler Name | E.R. Squibb & Sons, L.L.C. |
| Substance Name | STAVUDINE |
| Strength Number | 1 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |